DENTSPLY SIRONA (XRAY) Stifel Jaws & Paws Conference 2026 summary

Leadership and organizational changes

• CEO tenure began in August 2025, with a focus on talent acquisition and commercial reorganization exceeding expectations.

• Internal processes and approval mechanisms are being streamlined to support faster execution and customer focus.

• Restructuring aims to simplify operations, integrate historic acquisitions, and eliminate redundancies, freeing $120 million for reinvestment.

• Savings are being directed toward clinical education, rep training, R&D, and offsetting tariffs.

• Emphasis on making the company easier to do business with through lean methodology and common systems.

Market outlook and business performance

• U.S. and European markets show stable to slightly improving trends, with long-term optimism for Asia Pacific.

• Market fluctuations are acknowledged, but the focus remains on internal execution and turnaround.

• 1Q 2026 revenue declined, but sequential improvements are targeted to reach flat year-over-year growth by 4Q 2026.

• Inventory reduction in the channel is expected to be completed by the end of 2026.

Distribution strategy and channel management

• Expanded to five distributor agreements, with potential for modest further growth to optimize national and regional coverage.

• New drop ship model improves cash flow for distributors and enables better inventory control and production planning.

• Early results from new distributor partnerships, such as Benco, have been positive, with faster-than-expected sales traction.